DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

Cantor Fitzgerald Maintains Overweight on Aimmune Therapeutics, Raises Price Target to $64

Cantor Fitzgerald analyst Charles Duncan maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Overweight and raises the price target from $55 to $64.

Benzinga · 02/03/2020 12:15

Cantor Fitzgerald analyst Charles Duncan maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Overweight and raises the price target from $55 to $64.